FSD Pharma (NASDAQ: HUGE) is one of 33 public companies in the “Medicinals & botanicals” industry, but how does it weigh in compared to its peers? We will compare FSD Pharma to similar businesses based on the strength of its institutional ownership, earnings, analyst recommendations, valuation, risk, profitability and dividends.
This is a summary of recent recommendations for FSD Pharma and its peers, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|FSD Pharma Competitors||136||361||412||14||2.33|
As a group, “Medicinals & botanicals” companies have a potential upside of 108.41%. Given FSD Pharma’s peers higher probable upside, analysts clearly believe FSD Pharma has less favorable growth aspects than its peers.
Volatility & Risk
FSD Pharma has a beta of 0.37, suggesting that its share price is 63% less volatile than the S&P 500. Comparatively, FSD Pharma’s peers have a beta of 2.56, suggesting that their average share price is 156% more volatile than the S&P 500.
This table compares FSD Pharma and its peers’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|FSD Pharma Competitors||-163.69%||-267.59%||-46.37%|
Insider and Institutional Ownership
0.3% of FSD Pharma shares are held by institutional investors. Comparatively, 21.6% of shares of all “Medicinals & botanicals” companies are held by institutional investors. 25.8% of shares of all “Medicinals & botanicals” companies are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.
Earnings and Valuation
This table compares FSD Pharma and its peers revenue, earnings per share and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|FSD Pharma||$190,000.00||-$39.20 million||-0.39|
|FSD Pharma Competitors||$218.50 million||-$99.79 million||1.73|
FSD Pharma’s peers have higher revenue, but lower earnings than FSD Pharma. FSD Pharma is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.
FSD Pharma peers beat FSD Pharma on 8 of the 13 factors compared.
FSD Pharma Company Profile
FSD Pharma, Inc. is a specialty biotech pharmaceutical research and development company. It focuses on developing over time a robust pipeline of FDA-approved synthetic compounds targeting the endocannabinoid system of the human body to treat certain diseases of the central nervous system and autoimmune disorders of the skin, GI tract, and the musculoskeletal system. The company was founded by Thomas Fairfull, Zeeshan Saeed and Anthony J. Durkacz in 1994 and is headquartered in Cobourg, Canada.
Receive News & Ratings for FSD Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for FSD Pharma and related companies with MarketBeat.com's FREE daily email newsletter.